Advancing ADC Development
Can prodrug payloads lead to a new dawn for antibody drug conjugates?
Iksuda Therapeutics has licensed a class of tumor-activated prodrug payloads from the University of Goettingen and now hopes to develop a new generation of antibody drug conjugates (ADCs) based on protein-alkylating cytotoxicity.
“The ability to treat all patients safely, irrespective of the relative antigen level for a particular indication, would be a major step forward for the clinical success of ADCs,” says Dave Simpson, Iksuda CEO. “If the concept of broad ranging yet tumor specific activation could be deployed to ADCs, it would be a major step forward that adds another level of tumor specific targeting and improved safety.”
We spoke with Simpson to learn more about the challenges of ADCs – and the company’s hopes for the future.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine